Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385432 | 0.77 | ALDH1A1 (0.42) | ALDH1A1NPC1KDM4ECYP2A6CYP1A2 | |
| SCHEMBL3933846 | 0.77 | KDM4E (0.41) | ALDH1A1NPC1KDM4ECYP2A6CYP1A2 | |
| SCHEMBL2320187 | 0.74 | KDM4E (0.47) | ALDH1A1NPC1KDM4ECYP1A2TDP1 | |
| SCHEMBL2447211 | 0.73 | KDM4E (0.44) | ALDH1A1NPC1KDM4EPDE10ATDP1 | |
| SCHEMBL15229223 | 0.73 | ALDH1A1 (0.43) | ALDH1A1NPC1KDM4ETGFBR1POLB | |
| SCHEMBL12002555 | 0.72 | CYP2A6 (0.43) | NPC1KDM4ECYP2A6TDP1TGFBR1 | |
| SCHEMBL28358019 | 0.70 | CYP2A6 (0.45) | ALDH1A1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL628270 | 0.70 | ALDH1A1 (0.43) | ALDH1A1NPC1KDM4ECYP2A6PDE10A | |
| SCHEMBL7914703 | 0.69 | PDGFRB (0.50) | ALDH1A1NPC1KDM4ECYP2A6CYP1A2 | |
| SCHEMBL521935 | 0.69 | NQO2 (0.46) | ALDH1A1NPC1KDM4EPDE10ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4636486-B2 | — | — | 2011-02-23 | — | — | JP | claimed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | claimed |
| EP-1478358-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | BAYER CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2003068228-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242147-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1636585-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004113274-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1478358-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003068228-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | ALDH1A1 1345/4885NPC1 2683/4885KDM4E 1027/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | ALDH1A1 1345/4885NPC1 2683/4885KDM4E 1027/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | ALDH1A1 735/4885NPC1 3773/4885KDM4E 1247/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | ALDH1A1 1345/4885NPC1 2683/4885KDM4E 1027/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | ALDH1A1 1345/4885NPC1 2683/4885KDM4E 1027/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | ALDH1A1 1255/4885NPC1 2388/4885KDM4E 1076/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | ALDH1A1 1345/4885NPC1 2683/4885KDM4E 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.